Cargando…

NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors

BACKGROUND: PD-1/PD-L1 inhibitors have improved survival for patients with non-small cell lung cancer (NSCLC). We evaluated natural killer cell activity (NKA) and methylated HOXA9 circulating tumor DNA (ctDNA) as prognostic biomarkers in NSCLC patients treated with PD-1/PD-L1 inhibitors. METHODS: Pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Sara Witting Christensen, Nederby, Line, Andersen, Rikke Fredslund, Hansen, Torben Schjødt, Nyhus, Christa Haugaard, Hilberg, Ole, Jakobsen, Anders, Hansen, Torben Frøstrup
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307873/ https://www.ncbi.nlm.nih.gov/pubmed/37137997 http://dx.doi.org/10.1038/s41416-023-02285-z

Ejemplares similares

The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer
por: Wen, Sara Witting Christensen, et al.
Publicado: (2021)

Natural killer cell activity as a biomarker for the diagnosis of lung cancer in high-risk patients
por: Borg, Morten, et al.
Publicado: (2022)

Validating Methylated HOXA9 in Bronchial Lavage as a Diagnostic Tool in Patients Suspected of Lung Cancer
por: Wen, Sara W. C., et al.
Publicado: (2021)

Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis
por: Borg, Morten, et al.
Publicado: (2023)

The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
por: Dizdarevic, Edina, et al.
Publicado: (2022)

Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer—A Systematic Review
por: Wen, Sara Witting Christensen, et al.
Publicado: (2022)

Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
por: Hansen, Torben Frøstrup, et al.
Publicado: (2017)

Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy
por: Eriksen, Anne Haahr Mellergaard, et al.
Publicado: (2017)

Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma
por: Wen, Sara W. C., et al.
Publicado: (2020)

MicroRNA Expression Profiling to Identify and Validate Reference Genes for the Relative Quantification of microRNA in Rectal Cancer
por: Eriksen, Anne Haahr Mellergaard, et al.
Publicado: (2016)

Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer
por: Eriksen, Anne Haahr Mellergaard, et al.
Publicado: (2016)

NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer
por: Raunkilde, Louise, et al.
Publicado: (2022)

Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer()
por: Hansen, Torben Frøstrup, et al.
Publicado: (2019)

The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
por: Hansen, Torben Frøstrup, et al.
Publicado: (2012)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab
por: Andersen, Line Bechsgaard, et al.
Publicado: (2022)

Intra-tumoural vessel area estimated by expression of epidermal growth factor-like domain 7 and microRNA-126 in primary tumours and metastases of patients with colorectal cancer: a descriptive study
por: Hansen, Torben Frøstrup, et al.
Publicado: (2015)

Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA
por: Kjær, Ina Mathilde, et al.
Publicado: (2023)

NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer
por: Jensen, Lars Henrik, et al.
Publicado: (2019)

High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4(+) T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens
por: Iversen, Katrine Fladeland, et al.
Publicado: (2022)

Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
por: Hansen, Torben Frøstrup, et al.
Publicado: (2021)

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion
por: Alvarez, Maite, et al.
Publicado: (2020)

Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis
por: Sun, Rui, et al.
Publicado: (2020)

Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1
por: Makowska, Anna, et al.
Publicado: (2020)

PD-1 expression on mouse intratumoral NK cells and its effects on NK cell phenotype
por: Wagner, Arnika K., et al.
Publicado: (2022)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

Features of Memory-Like and PD-1(+) Human NK Cell Subsets
por: Della Chiesa, Mariella, et al.
Publicado: (2016)

Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance
por: del Rio, Maria-Luisa, et al.
Publicado: (2022)

Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression
por: Giuliani, Massimo, et al.
Publicado: (2017)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort
por: Hansen, Torben Frøstrup, et al.
Publicado: (2014)

PD-L1 blockade enhances anti-tumor efficacy of NK cells
por: Oyer, Jeremiah L., et al.
Publicado: (2018)

Interferon β and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells
por: Makowska, Anna, et al.
Publicado: (2019)

Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
por: Trabjerg, Natacha Dencker, et al.
Publicado: (2019)

Comorbidity among Danish lung cancer patients before and after initial cancer diagnosis
por: Gouliaev, Anja, et al.
Publicado: (2020)

HOXA11-AS1 Promotes PD-L1-Mediated Immune Escape and Metastasis of Hypopharyngeal Carcinoma by Facilitating PTBP1 and FOSL1 Association
por: Zhou, Zheng, et al.
Publicado: (2022)

PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
por: Pico de Coaña, Yago, et al.
Publicado: (2020)

Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression
por: Bellucci, Roberto, et al.
Publicado: (2015)

PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression
por: Mariotti, Francesca R., et al.
Publicado: (2018)

PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
por: Beldi-Ferchiou, Asma, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_od3c2rvvj0kgbbbok6kgbhenks